Crawley, UK: Virgin Atlantic Cargo is increasing temperature-controlled services after more than doubling its share of the pharmaceutical market from the UK to North America since the launch of its Cool Chain product two years ago.
Virgin is approved to carry temperature-controlled active cargo containers from CSafe and Envirotainer
Darren Sherlock, manager, products and partnerships, heads the development. He was part of the team that developed Virgin Atlantic’s Cool Chain product in 2014.
Virgin Atlantic’s Cool Chain product is designed to support passive shipments in the 15-25°C and 2-8°C ranges, based on its Just Ride and Must Ride services. Pharma shipments booked as Must Ride have priority access to capacity and a 100% money back guarantee.
The airline is also approved to carry temperature-controlled active cargo containers from partners CSafe and Envirotainer and leases containers on behalf of its customers on request.
John Lloyd, senior vice president, cargo, Virgin Atlantic, said: “Pharmaceutical traffic is a fast-growing part of Virgin’s business. The world’s biggest global pharma market is transatlantic so with our 27% share of cargo capacity to and from the US we are in a strong position to give our customers the capacity, frequencies and service they need. Building on the growth we achieved in 2015, Darren will be responsible for working closely with our customers to look for more opportunities for us to work together across our network.”
Sherlock said: “Pharmaceutical shipments cover such a broad range of products from contact lenses to high value vaccines. Our growth is based on understanding the sensitivities of every shipment, being responsive to our customers and tailoring services to meet their requirements.
“Some pharma customers moving less temperature sensitive products, for example, choose to use our high value cargo service to provide added security. Our reputation for great customer service gives customers confidence that we will deliver the service we have promised and they know we will be honest about what we can and cannot offer them on a lane-by-lane basis. With the UK to US pharma market alone forecast to grow by 7% a year to 2020, we expect to see more opportunities over this period,” Sherlock said.
Posted on July 6, 2016
by Edwin Kalischnig